Imatinib mesylate (Gleevec) plus hydroxyurea: An effective regimen in the treatment of recurrent malignant glioma: Phase 2 study results

被引：0
|
作者：
Reardon, DA
Quinn, J
Rich, J
Vredenburgh, J
Desjardins, A
Sathornsumetee, S
Salvado, A
Nikolova, Z
Bigner, D
Friedman, H
机构：
[1] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA
[2] Novartis Pharmaceut Corp, E Hanover, NJ USA
来源：
NEURO-ONCOLOGY | 2005年 / 7卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
35
引用
下载
收藏
页码：291 / 291
页数：1
相关论文
共 50 条
  • [1] Efficacy of imatinib mesylate plus hydroxyurea regimen in the treatment of recurrent malignant glioma: Phase II study results
    Friedman, HS
    Quinn, J
    Rich, J
    Vredenburgh, J
    Desjardins, A
    Sathornsumetee, S
    Salvado, A
    Nikolova, Z
    Bigner, D
    Reardon, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 117S - 117S
  • [2] FINAL RESULTS OF A PHASE II STUDY OF IMATINIB MESYLATE (GLEEVEC) PLUS HYDROXYUREA FOR ADULTS WITH RECURRENT/PROGRESSIVE LOW-GRADE GLIOMA
    Reardon, David A.
    Peters, Katherine
    Desjardins, Annick
    Sampson, John
    Vredenburgh, James J.
    Gururangan, Sri
    Friedman, Henry S.
    NEURO-ONCOLOGY, 2010, 12 : 49 - 49
  • [3] VANDETANIB, IMATINIB MESYLATE, AND HYDROXYUREA FOR RECURRENT MALIGNANT GLIOMA: A PHASE I STUDY
    Desjardins, Annick
    Vredenburgh, James J.
    Gururangan, Sridharan
    Peters, Katherine B.
    Friedman, Allan H.
    Friedman, Henry
    Reardon, David A.
    NEURO-ONCOLOGY, 2009, 11 (05) : 634 - 634
  • [4] PHASE I STUDY OF VANDETANIB, IMATINIB MESYLATE, AND HYDROXYUREA FOR RECURRENT MALIGNANT GLIOMA
    Reardon, David A.
    Vredenburgh, James. L.
    Desjardins, Annick
    Gururangan, Sridharan
    Peters, Katherine B.
    Boulton, Susan T.
    NEURO-ONCOLOGY, 2009, 11 (06) : 946 - 946
  • [5] Phase I study of vandetanib, imatinib mesylate, and hydroxyurea for recurrent malignant glioma
    Kirkpatrick, J. P.
    Vredenburgh, J. J.
    Desjardins, A.
    Gururangan, S.
    Peters, K. B.
    Boulton, S. T.
    Friedman, A. H.
    Friedman, H. S.
    Reardon, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Phase II trial of imatinib mesylate plus hydroxyurea in the treatment of patients with malignant glioma
    Reardon, D
    Friedman, A
    Herndon, J
    Quinn, J
    Rich, J
    Vredenburgh, J
    Badruddoja, M
    Desjardins, A
    Sampson, J
    Gururangan, S
    Dowell, J
    Affronti, M
    Allen, D
    Jackson, S
    Zeigler, K
    Silverman, S
    Tourt-Uhlig, S
    Silverman, S
    Salvado, A
    Nikolova, Z
    Bigner, D
    Friedman, H
    NEURO-ONCOLOGY, 2004, 6 (04) : 381 - 381
  • [7] Imatinib mesylate plus hydroxyurea for adults with recurrent/progressive low-grade glioma: Final phase II study results
    Peters, K.
    Desjardins, A.
    Vredenburgh, J. J.
    Dryman, B.
    Gururangan, S.
    Friedman, H. S.
    Reardon, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] A phase I trial of imatinib (GLEEVEC), hydroxyurea and RAD001 for patients with recurrent malignant glioma
    Desjardins, A.
    Quinn, J. A.
    Rich, J. N.
    Vredenburgh, J. J.
    Sathornsumetee, S.
    Gururangan, S.
    Friedman, A. H.
    Berg, W.
    Egorin, M. J.
    Salvado, A.
    Friedman, H. S.
    Reardon, D. A.
    NEURO-ONCOLOGY, 2006, 8 (04) : 441 - 441
  • [9] Phase II trial of imatinib mesylate (GLEEVEC) and hydroxyurea for adults with recurrent/progressive meningioma
    Goli, Krishna
    Bota, Daniela
    Desjardins, Annick
    Rich, Jeremy
    Vredenburgh, James
    Quinn, Jennifer
    Sathornsumetee, Sith
    Salvado, August
    Friedman, Henry
    Reardon, David
    NEURO-ONCOLOGY, 2007, 9 (04) : 519 - 519
  • [10] Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas
    Annick Desjardins
    Jennifer A. Quinn
    James J. Vredenburgh
    Sith Sathornsumetee
    Allan H. Friedman
    James E. Herndon
    Roger E. McLendon
    James M. Provenzale
    Jeremy N. Rich
    John H. Sampson
    Sridharan Gururangan
    Jeannette M. Dowell
    August Salvado
    Henry S. Friedman
    David A. Reardon
    Journal of Neuro-Oncology, 2007, 83 : 53 - 60
12345